Institute of Nephrology, Zhong Da Hospital, School of Medicine, Southeast University, Nanjing, 210009, China.
J Mol Histol. 2013 Dec;44(6):693-703. doi: 10.1007/s10735-013-9521-8. Epub 2013 Aug 2.
Recent studies have shown that chronic endothelial dysfunction can impair multiple aspects of renal physiology and, in turn, contribute to renal fibrosis. Sphingosine 1-phosphate (S1P) has been highlighted as an endothelial barrier-stabilizing mediator. The aim of our study was to investigate the effect of FTY720, an S1P analog, on the progression of renal fibrosis by inhibiting renal microvasculature endothelial dysfunction in a rat model of chronic kidney disease. Thirty male Sprague-Dawley rats were used in this study. Seven days after surgery, we placed the animals into three groups: sham surgery; 5/6 nephrectomized (Nx) rats; and 5/6Nx + FTY720 (1 mg/kg/day). All of the animals were sacrificed 12 weeks after surgery. We obtained and analyzed blood and kidney tissue samples from all of the groups. Glomerular capillary density and peritubular capillary (PTC) density were determined by CD31 immunostaining. The expression of transforming growth factor beta 1 (TGF-β1), collagen IV, fibronectin, endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) were analyzed by immunohistochemistry, reverse transcription-polymerase chain reaction and western blotting. The 5/6Nx group exhibited increased blood urea nitrogen and serum creatinine, visible renal histological changes, pro-fibrotic molecule (TGF-β1) and production of extracellular matrix proteins such as collagen IV and fibronectin and decreased glomerular and PTC density, compared to the sham controls (P < 0.01). We observed that treatment with FTY720 reduced these abnormalities. Furthermore, the level of NO, the expression levels of eNOS and VEGF were downregulated in the kidney tissue in 5/6Nx rats, FTY720 treatment significantly attenuated this decrease. FTY720 prevents the progression of renal fibrosis by inhibiting renal microvasculature endothelial dysfunction in a rat model of chronic kidney disease.
最近的研究表明,慢性内皮功能障碍可损害肾脏生理的多个方面,并进而导致肾纤维化。1-磷酸鞘氨醇(S1P)已被强调为一种内皮屏障稳定介质。我们的研究目的是通过抑制慢性肾脏病大鼠模型中的肾微血管内皮功能障碍来研究 FTY720(一种 S1P 类似物)对肾纤维化进展的影响。本研究使用了 30 只雄性 Sprague-Dawley 大鼠。手术后 7 天,我们将动物分为三组:假手术组;5/6 肾切除(Nx)大鼠;和 5/6Nx+FTY720(1mg/kg/天)。所有动物均在手术后 12 周处死。我们从所有组中获取并分析了血液和肾脏组织样本。通过 CD31 免疫染色测定肾小球毛细血管密度和肾小管周毛细血管(PTC)密度。通过免疫组织化学,逆转录-聚合酶链反应和蛋白质印迹分析转化生长因子β1(TGF-β1),胶原 IV,纤连蛋白,内皮型一氧化氮合酶(eNOS)和血管内皮生长因子(VEGF)的表达。与假手术对照组相比,5/6Nx 组的血尿素氮和血清肌酐升高,肾脏组织学变化明显,促纤维化分子(TGF-β1)和细胞外基质蛋白如胶原 IV 和纤连蛋白的产生增加,肾小球和 PTC 密度降低(P <0.01)。我们观察到 FTY720 治疗可减轻这些异常。此外,5/6Nx 大鼠肾脏组织中 NO 水平,eNOS 和 VEGF 的表达水平降低,FTY720 治疗可显著减弱这种降低。FTY720 通过抑制慢性肾脏病大鼠模型中的肾微血管内皮功能障碍来预防肾纤维化的进展。